ImmunoPrecise Antibodies Ltd. (IPA): Price and Financial Metrics


ImmunoPrecise Antibodies Ltd. (IPA): $5.30

-0.15 (-2.75%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IPA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IPA POWR Grades


  • IPA scores best on the Sentiment dimension, with a Sentiment rank ahead of 70.37% of US stocks.
  • IPA's strongest trending metric is Sentiment; it's been moving up over the last 53 days.
  • IPA ranks lowest in Quality; there it ranks in the 8th percentile.

IPA Stock Summary

  • IPA's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 2.56 -- higher than just 11.22% of US-listed equities with positive expected earnings growth.
  • ImmunoPrecise Antibodies Ltd's stock had its IPO on December 31, 2020, making it an older stock than merely 1.37% of US equities in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.18 for ImmunoPrecise Antibodies Ltd; that's greater than it is for only 11.86% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ImmunoPrecise Antibodies Ltd are GAN, CASI, ASXC, STRM, and CTXS.
  • IPA's SEC filings can be seen here. And to visit ImmunoPrecise Antibodies Ltd's official web site, go to www.immunoprecise.com.

IPA Price Target

For more insight on analysts targets of IPA, see our IPA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $16.17 Average Broker Recommendation 1.5 (Moderate Buy)

IPA Stock Price Chart Interactive Chart >

Price chart for IPA

IPA Price/Volume Stats

Current price $5.30 52-week high $16.47
Prev. close $5.45 52-week low $3.51
Day low $5.17 Volume 35,000
Day high $5.59 Avg. volume 32,640
50-day MA $5.14 Dividend yield N/A
200-day MA $5.71 Market Cap 129.77M

ImmunoPrecise Antibodies Ltd. (IPA) Company Bio


ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.


IPA Latest News Stream


Event/Time News Detail
Loading, please wait...

IPA Latest Social Stream


Loading social stream, please wait...

View Full IPA Social Stream

Latest IPA News From Around the Web

Below are the latest news stories about ImmunoPrecise Antibodies Ltd that investors may wish to consider to help them evaluate IPA as an investment opportunity.

ImmunoPrecise''s COVID-19 Antibody Cocktail Shows Neutralization Activity Against Omicron

Immunoprecise Antibodies Ltd (NASDAQ: IPA ) has released preclinical data for the PolyTope TATX-03 COVID-19 antibody cocktail. The data demonstrated robust neutralizing potency of the antibody cocktail towards the omicron variant (B.1.1.529) in in vitro pseudovirus assays. The Company believes that it possesses the only first-generation cocktail Full story available on Benzinga.com

Benzinga | January 31, 2022

Immunotherapeutic PolyTope® from ImmunoPrecise (IPA) Potently Neutralizes the SARS-CoV-2 Omicron Variant – Moves Towards FDA/IND-Submission

VICTORIA, British Columbia, January 31, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company") (NASDAQ: IPA) (TSXV: IPA) is pleased to announce the release of data demonstrating strong neutralizing potency of its PolyTope® TATX-03 antibody cocktail towards the SARS-CoV-2 Omicron variant (B.1.1.529) in in vitro pseudovirus assays. This first generation four antibody cocktail against SARS-CoV-2 was rationally designed to sustain efficacy against all SARS-CoV-2 strains and variants with the goal

Yahoo | January 31, 2022

ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Operations and Environmental Sustainability

VICTORIA, British Columbia & OSS, Netherlands, January 18, 2022--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) today announced the relocation of its IPA Europe Oss laboratories to a new multi-tenant biotech Center of Excellence at the Pivot Park Campus in Oss, Netherlands.

Yahoo | January 18, 2022

ImmunoPrecise Antibodies Announces Grant of Stock Options

VICTORIA, British Columbia, January 17, 2022--IMMUNOPRECISE ANTIBODIES LTD. ("IPA" or the "Company") (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery, today announced that on January 13, 2022 its board of directors approved the grant of 15,000 stock options (the "Options") under its stock option plan to acquire up to an aggregate of 15,000 common shares in the capital of IPA ("Common Shares"). The Options were granted to a certain officer of IPA. Each Option is

Yahoo | January 17, 2022

Investors in ImmunoPrecise Antibodies (CVE:IPA) have made a impressive return of 113% over the past three years

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can...

Yahoo | January 16, 2022

Read More 'IPA' Stories Here

IPA Price Returns

1-mo -4.68%
3-mo 12.77%
6-mo -10.77%
1-year -32.23%
3-year N/A
5-year N/A
YTD -1.12%
2021 -64.15%
2020 579.08%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5424 seconds.